APOA1 and nervous system disorder: These molecular modifications help explain why certain ApoA-I mimetic peptides and reconstituted HDL formulations, despite demonstrating efficacy in vitro, have failed to show consistent therapeutic benefits in clinical trials for neurological diseases.